It looks like you're offline.
Open Library logo
additional options menu

MARC Record from marc_columbia

Record ID marc_columbia/Columbia-extract-20221130-019.mrc:93480724:2586
Source marc_columbia
Download Link /show-records/marc_columbia/Columbia-extract-20221130-019.mrc:93480724:2586?format=raw

LEADER: 02586cam a2200361 a 4500
001 9301568
005 20120418213616.0
008 111204s2012 dcua b 100 0 eng c
020 $a9780309219297
020 $a0309219299
035 $a(OCoLC)ocn767570602
035 $a(OCoLC)767570602
035 $a(NNC)9301568
040 $aBTCTA$beng$cBTCTA$dUPM$dAAA
042 $apcc
043 $an-us---
050 4 $aR853.C55$bP82 2011
111 2 $aPublic Engagement and Clinical Trials: New Models and Disruptive Technologies$d(2011 :$cMount Sinai School of Medicine)
245 10 $aPublic engagement and clinical trials :$bnew models and disruptive technologies : workshop summary /$cVictoria Weisfeld, Rebecca A. English, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
260 $aWashington, D.C. :$bNational Academies Press,$cc2012.
300 $axvi, 124 p. :$b1 col. ill. ;$c23 cm.
505 0 $aIntroduction -- Recruitment challenges in clinical trials for different diseases and conditions -- Models for public engagement -- Messages and methods for public engagement -- The media -- Novel clinical trials designs -- The health system's structure and culture -- Toward a patient-centered strategy for clinical trials.
520 $aClinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition among many stakeholders that the U.S. clinical trials enterprise is unable to keep pace with the national demand for research results. The IOM, along with the Mount Sinai School of Medicine, held a workshop June 27-28, 2011, to engage stakeholders and experts in a discussion about possible solutions to improve public engagement in clinical trials.
504 $aIncludes bibliographical references (p. 85-87).
530 $aAlso available in Open Book format via the National Academies Press home page.
650 0 $aClinical trials$zUnited States$vCongresses.
700 1 $aWeisfeld, Victoria D.
700 1 $aEnglish, Rebecca A.
700 1 $aClaiborne, Anne B.
710 2 $aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation.
710 2 $aMount Sinai School of Medicine.
856 41 $uhttp://www.nap.edu/catalog.php?record_id=13237
852 00 $boff,sci$hR853.C55$iP82 2011g